European Journal of Cancer最新文献

{"title":"Letter re: Validation and development of a refined M1 category for nasopharyngeal carcinoma based on the version-nine of AJCC/UICC TNM staging system in the immunotherapy era: A multicenter cohort study","authors":"Xudong Zhu","doi":"10.1016/j.ejca.2025.115383","DOIUrl":"10.1016/j.ejca.2025.115383","url":null,"abstract":"","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"220 ","pages":"Article 115383"},"PeriodicalIF":7.6,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143771492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Matching-adjusted indirect comparison of endoscopic and craniofacial resection for the treatment of sinonasal cancer invading the skull base","authors":"Florian Chatelet ,&nbsp;Sylvie Chevret ,&nbsp;Alessandro Vinciguerra ,&nbsp;Giacomo Bertazzoni ,&nbsp;Domitille Camous ,&nbsp;Marco Ferrari ,&nbsp;Davide Mattavelli ,&nbsp;Mario Turri-Zanoni ,&nbsp;Alberto Schreiber ,&nbsp;Stefano Taboni ,&nbsp;Vittorio Rampinelli ,&nbsp;Alberto Daniele Arosio ,&nbsp;Cesare Piazza ,&nbsp;Paolo Battaglia ,&nbsp;Maurizio Bignami ,&nbsp;Alberto Deganello ,&nbsp;Paolo Castelnuovo ,&nbsp;Piero Nicolai ,&nbsp;Philippe Herman ,&nbsp;Benjamin Verillaud","doi":"10.1016/j.ejca.2025.115382","DOIUrl":"10.1016/j.ejca.2025.115382","url":null,"abstract":"<div><h3>Aim</h3><div>The aim of this study was to compare the efficacy and safety of endoscopic endonasal approaches (EEA) with craniofacial resection (CFR) for sinonasal cancers invading the skull base, using an unanchored matching-adjusted indirect comparison (MAIC).</div></div><div><h3>Methods</h3><div>A MAIC approach was used to analyse data from two large cohorts: the MUlti-institutional collaborative Study on Endoscopically treated Sinonasal cancers (MUSES) cohort, comprising sinonasal cancer patients treated endoscopically, and a historical CFR cohort reported by Ganly et al. Individual patient data were available only for the first cohort. Patients with olfactory neuroblastomas were excluded. Key prognostic factors were used to match and adjust the two cohorts, minimising selection bias. The primary endpoint was overall survival (OS), with secondary endpoints including recurrence-free survival (RFS), perioperative mortality, complication rates, and resection margins.</div></div><div><h3>Results</h3><div>A total of 724 EEA-treated and 334 CFR-treated patients were included. EEA showed significantly improved OS before (HR= 2.33, 95 % CI= 1.88–2.87) and after MAIC adjustment (HR= 1.93, 95 % CI= 1.60–2.34). Observed RFS was higher in the EEA group (HR= 1.39, 95 % CI = 1.14–1.69) but no longer differed after adjustment (HR= 1.06, 95 % CI= 0.91–1.23). EEA was associated with significantly better Disease Specific Survival (HR= 1.71, 95 % CI = 1.39–2.13), lower perioperative mortality (OR= 8.12, 95 % CI= 3.45–36.7) and fewer complications than CFR (OR= 3.68, 95 % CI= 2.47–5.42).</div></div><div><h3>Conclusion</h3><div>In this MAIC study based on the 2 largest cohorts of sinonasal cancer with skull base invasion, EEA offered comparable oncologic outcomes to CFR with reduced morbidity, supporting it as a valid alternative when performed in expert centres.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"220 ","pages":"Article 115382"},"PeriodicalIF":7.6,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143705194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiomic markers associated with clinical benefit in patients with radiographic progression of advanced uveal melanoma on tebentafusp","authors":"Volkan Beylergil ,&nbsp;Laura Collins ,&nbsp;Lawrence H. Schwartz ,&nbsp;Thomas Eche ,&nbsp;Binsheng Zhao ,&nbsp;Stephane Champiat ,&nbsp;Richard Carvajal ,&nbsp;Shaad E. Abedin ,&nbsp;Laurent Dercle","doi":"10.1016/j.ejca.2025.115386","DOIUrl":"10.1016/j.ejca.2025.115386","url":null,"abstract":"<div><h3>Study aim</h3><div>Tebentafusp, a bispecific fusion protein consisting of affinity-enhanced T cell receptor fused to anti-CD3 effector, has shown overall survival (OS) benefits across all RECIST response categories, including progressive disease (PD). In a phase 2 trial (NCT02570308) for advanced uveal melanoma (mUM), 35 % of PD patients experienced ≥ 0.5 log ctDNA reduction, resulting in a median overall survival (OS) of ∼17 months, compared to ∼8 months in the non-ctDNA reduction group.</div></div><div><h3>Methods</h3><div>A total of 34 of 127 2L+ mUM patients with PD were split into two groups based on absence or presence of ctDNA reduction (≥0.5 log reduction). Lesions from CT and MRI scans were analyzed using radiomics features at baseline and week eight, yielding two machine-learning-derived patient signatures (16 features). Performance of per-patient analysis (n = 32) and per-lesion analysis (n = 148) was assessed using ROC AUC (95 % confidence interval [CI]).</div></div><div><h3>Results</h3><div>In the per-patient analysis, a volumetric signature classified patients into groups with ROC AUC of 0.71 [0.53–0.90] with 63 % specificity and 81 % sensitivity at the optimal threshold (0.57). In the per-lesion analysis, a radiomic signature reached an ROC AUC of 0.70 [0.58–0.81] with 66 % specificity and 74 % sensitivity at the optimal threshold (0.53). Group B had lower baseline tumor lesion volume (ROC AUC=0.65), distinct baseline (ROC AUC=0.66), and change by week eight (ROC AUC=0.66/0.69 on CT/MRI) in tumor heterogeneity.</div></div><div><h3>Conclusion</h3><div>Radiomic analysis accurately predicted ctDNA reduction in PD patients at both the patient and lesion level. The most influential predictor was decreased tumor heterogeneity observed on CT/MRI.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"220 ","pages":"Article 115386"},"PeriodicalIF":7.6,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143748555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tissue-agnostic target profiles and treatment efficacy in cancer patients: Insights from the C-CAT clinicogenomic repository","authors":"Rui Kitadai ,&nbsp;Yusuke Okuma ,&nbsp;Taro Shibata ,&nbsp;Takashi Kohno ,&nbsp;Takafumi Koyama","doi":"10.1016/j.ejca.2025.115380","DOIUrl":"10.1016/j.ejca.2025.115380","url":null,"abstract":"<div><h3>Purpose</h3><div>Utilizing real-world data from Japan's C-CAT clinicogenomic repository, our study demonstrates a significant shift in cancer management through cancer genomic profiling (CGP) tests. The aim of this study is assessing the prevalence of cross-organ targeted genetic alterations and exploring the differences in treatment responses among cancer patients who underwent CGP tests.</div></div><div><h3>Methods</h3><div>Analyzing data from 60,256 patients in the C-CAT repository, we documented the prevalence of FDA-approved biomarkers, cross-organ genetic alterations, and treatment outcomes for tissue-agnostic therapies from June 2019 to December 2023.</div></div><div><h3>Results</h3><div>Biomarkers including <em>RET</em> rearrangement, <em>BRAF</em>^{<em>V600E</em>} mutation, and <em>NTRK</em> rearrangement showed varied therapeutic responses, underscoring the need for universal CGP testing to optimize patient outcomes. Notably, our findings highlight variations in response across different age groups, suggesting the potential for age-specific treatment strategies. Comparisons with the AACR Project GENIE database revealed broader implications for the global genomic landscape.</div></div><div><h3>Conclusion</h3><div>This study emphasizes the crucial role of clinicogenomic repositories in advancing precision oncology across diverse populations, underscoring the utility of integrating clinical and genomic data in national repositories.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"220 ","pages":"Article 115380"},"PeriodicalIF":7.6,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143734642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patterns of disease dissemination and survival in patients with synchronous and metachronous metastatic pancreatic adenocarcinoma: Nationwide population-based study","authors":"Merlijn U.J.E. Graus ,&nbsp;Aniek E. van Diepen ,&nbsp;Kim Josemanders ,&nbsp;Marc G. Besselink ,&nbsp;Stefan A.W. Bouwense ,&nbsp;Lois A. Daamen ,&nbsp;Ignace H.J.T. de Hingh ,&nbsp;Evelien J.M. de Jong ,&nbsp;Hanneke W.M. van Laarhoven ,&nbsp;Vincent E. de Meijer ,&nbsp;I. Quintus Molenaar ,&nbsp;Martijn W.J. Stommel ,&nbsp;Liselot B.J. Valkenburg-van Iersel ,&nbsp;Johanna W. Wilmink ,&nbsp;Lydia G.M. van der Geest ,&nbsp;Judith de Vos-Geelen ,&nbsp;for the Dutch Pancreatic Cancer Group","doi":"10.1016/j.ejca.2025.115385","DOIUrl":"10.1016/j.ejca.2025.115385","url":null,"abstract":"<div><h3>Aim</h3><div>Despite advances in understanding pancreatic adenocarcinoma, evidence on its metastatic patterns and impact on patient survival remains limited. This study aims to identify patterns of disease dissemination in synchronous versus metachronous metastatic pancreatic adenocarcinoma (mPAC) and their association with overall survival (OS).</div></div><div><h3>Methods</h3><div>Patients diagnosed with synchronous- or metachronous-mPAC were selected from the Netherlands Cancer Registry (2015–2021). Patient, tumor, and treatment characteristics were compared using Chi-squared tests. Survival data, calculated from detection of metastatic disease (OS-M), were analyzed using Kaplan-Meier and Log-rank tests.</div></div><div><h3>Results</h3><div>Overall, 10,788 patients with synchronous- and 508 with metachronous-mPAC were included. Median time to first metastasis in metachronous-mPAC was 13.2 months (IQR 9–23), varying significantly by metastatic site (liver-only 11.5; lung-only 28.0 months). Compared to synchronous-mPAC, patients with metachronous-mPAC had less liver metastases (48 % versus 75 %, p &lt; 0.001), but more lung (29 % versus 21 %, p &lt; 0.001) and peritoneal (35 % versus 25 %, p &lt; 0.001) metastases. Synchronous metastases to liver-only, lung-only, lymph node-only, or multiple sites at first diagnosis had a median OS-M that was (nearly) half compared to metachronous metastases to the same sites. Bone-only or peritoneum-only metastases in synchronous-mPAC showed a median OS-M comparable to metachronous-mPAC.</div></div><div><h3>Conclusion</h3><div>This nationwide population-based study reveals that metachronous-mPAC less commonly presents with liver metastases and more often metastasizes to lung, peritoneum or other atypical sites compared to synchronous-mPAC. These distinct metastatic patterns and their differences in survival may help enhance the prognostic estimation for individual patients from the detection of metastatic disease and warrants further research into the biology underlying metastasis development.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"220 ","pages":"Article 115385"},"PeriodicalIF":7.6,"publicationDate":"2025-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143705193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unraveling the clinical impact of differential DNA methylation in PDAC: A systematic review","authors":"Julia Adriana Kasmirski,&nbsp;Raj Roy,&nbsp;Christopher Wu,&nbsp;Lauren Wheeler,&nbsp;K. Kerrick Akinola,&nbsp;Herbert Chen,&nbsp;J. Bart Rose,&nbsp;Changde Cheng,&nbsp;Smita Bhatia,&nbsp;Andrea Gillis","doi":"10.1016/j.ejca.2025.115384","DOIUrl":"10.1016/j.ejca.2025.115384","url":null,"abstract":"<div><h3>Introduction</h3><div>Despite significant efforts to improve clinical outcomes, pancreatic ductal adenocarcinoma (PDAC) has a high mortality rate. The poor prognosis associated with this disease is multifactorial and associated with a highly variable genetic profile associated with its pathogenesis. Epigenetic modifications including DNA methylation further affect the expression of genetic material. However, there is no comprehensive understanding of the clinical impact of DNA methylation in PDAC.</div></div><div><h3>Methods</h3><div>A systematic literature review was registered on the International Prospective Register of Systematic Reviews database (CRD42023451955) and followed Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. An electronic search was conducted using the following databases: CINAHL Plus, Cochrane Library, Embase, Web of Science, Ovid Medline, and Google Scholar. Inclusion criteria included studies of patients with a PDAC diagnosis and information regarding genes or CpG sites that potentially affect diagnosis, prognosis, or survival of PDAC.</div></div><div><h3>Results</h3><div>The initial search retrieved 2402 articles, and 423 duplicates were excluded. After exclusion criteria was applied, 19 studies were included. The most common genes recorded as affecting tumor pathogenesis were <em>SFRP1</em> (n = 3/19, 15.7 %) and <em>NPTX2</em> (n = 2/19, 10,5 %). Studies indicated that hypermethylation of <em>SFRP1</em> and <em>NPTX2</em> were associated with poor prognosis.</div></div><div><h3>Conclusions</h3><div>PDAC is associated with a range of epigenetic modifications. Methylation of specific genes related to PDAC may influence survival and prognosis and be a therapeutic target. Individual patient epigenetic analysis may be a future direction in directing PDAC treatment and prognosis.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"220 ","pages":"Article 115384"},"PeriodicalIF":7.6,"publicationDate":"2025-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143724060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immunotherapy followed by cetuximab in locally advanced/metastatic cutaneous squamous cell carcinomas: the I-TACKLE trial","authors":"Paolo Bossi ,&nbsp;Andrea Alberti ,&nbsp;Cristiana Bergamini ,&nbsp;Carlo Resteghini ,&nbsp;Laura Deborah Locati ,&nbsp;Salvatore Alfieri ,&nbsp;Stefano Cavalieri ,&nbsp;Elena Colombo ,&nbsp;Cristina Gurizzan ,&nbsp;Luigi Lorini ,&nbsp;Valeria Tovazzi ,&nbsp;Manuel Zamparini ,&nbsp;Marco Ravanelli ,&nbsp;Paolo Antonio Ascierto ,&nbsp;Vittorio Rampinelli ,&nbsp;Alberto Grammatica ,&nbsp;Roberto Patuzzo ,&nbsp;Andrea Maurichi ,&nbsp;Lisa Francesca Licitra","doi":"10.1016/j.ejca.2025.115379","DOIUrl":"10.1016/j.ejca.2025.115379","url":null,"abstract":"<div><h3>Background</h3><div>Immunotherapy with pembrolizumab and cemiplimab achieves an overall response rate (ORR) of 34–51 % in locally advanced/metastatic (LA/M) cSCC, but primary and acquired resistance remains a challenge. This study evaluates whether adding cetuximab to pembrolizumab can overcome resistance by reducing immune escape.</div></div><div><h3>Patients and methods</h3><div>I-TACKLE is a phase II, open-label trial conducted at three Italian centers. Patients received intravenous pembrolizumab 200 mg every 3 weeks, and cetuximab was added in cases of stable disease or progression. The primary endpoint was cumulative ORR by a single agent or by combination strategy. Secondary endpoints included safety, progression-free survival (PFS), overall survival (OS), and response duration.</div></div><div><h3>Results</h3><div>From May 2019 to April 2021, 43 patients were enrolled and treated with pembrolizumab, and 23 received combination therapy. Median treatment durations were 3 months (pembrolizumab) and 4 months (combination). Cumulative ORR was 63 % [95 % CI 48–77], with 19/43 (44 %) responding to pembrolizumab and 8/21 (38 %) responding to the combination after resistance. Both patients experiencing an acquired resistance to pembrolizumab obtained partial response when cetuximab was introduced. Overall, 10/23 (44 %) responded to the combination. One-year PFS was 51 % with pembrolizumab and 42 % with combination therapy. Grade 3–4 treatment-related adverse events occurred in 7/43 (16 %) during pembrolizumab and 8/23 (35 %) during combination therapy, primarily dermatitis (30 %).</div></div><div><h3>Conclusions</h3><div>In LA/M cSCC, the addition of cetuximab to pembrolizumab reverts primary and acquired resistance with manageable toxicities. This sequential approach warrants further study.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"220 ","pages":"Article 115379"},"PeriodicalIF":7.6,"publicationDate":"2025-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143724816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Long-term follow-up, crossover, and rechallenge with pembrolizumab in the phase III KEYNOTE-716 study","authors":"Jason J. Luke ,&nbsp;Paolo A. Ascierto ,&nbsp;Muhammad A. Khattak ,&nbsp;Piotr Rutkowski ,&nbsp;Michele Del Vecchio ,&nbsp;Francesco Spagnolo ,&nbsp;Jacek Mackiewicz ,&nbsp;Luis de la Cruz Merino ,&nbsp;Vanna Chiarion-Sileni ,&nbsp;John M. Kirkwood ,&nbsp;Caroline Robert ,&nbsp;Dirk Schadendorf ,&nbsp;Federica de Galitiis ,&nbsp;Matteo S. Carlino ,&nbsp;Reinhard Dummer ,&nbsp;Peter Mohr ,&nbsp;Amos Odeleye-Ajakaye ,&nbsp;Mizuho Fukunaga-Kalabis ,&nbsp;Clemens Krepler ,&nbsp;Alexander M.M. Eggermont ,&nbsp;Georgina V. Long","doi":"10.1016/j.ejca.2025.115381","DOIUrl":"10.1016/j.ejca.2025.115381","url":null,"abstract":"<div><h3>Background</h3><div>Adjuvant pembrolizumab prolonged recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) in patients with resected stage IIB/IIC melanoma in KEYNOTE-716. Results of a post hoc 4-year analysis are reported, including progression/recurrence-free survival 2 (PRFS2).</div></div><div><h3>Methods</h3><div>Patients were randomly assigned 1:1 to pembrolizumab 200 mg or placebo intravenously every 3 weeks (part 1). RFS was the primary end point; DMFS was secondary. Patients with recurrence following placebo or 17 cycles of pembrolizumab could cross over to or be rechallenged with pembrolizumab (part 2).</div></div><div><h3>Results</h3><div>Median follow-up (n = 976) was 52.8 months (range, 39.4–64.8). RFS (HR, 0.62 [95 % CI, 0.50–0.78]) and DMFS (HR, 0.59 [0.45–0.77]) favored pembrolizumab. At 48 months, RFS rates were 71.3 % for pembrolizumab and 58.3 % for placebo, and DMFS rates were 81.0 % and 70.1 %, respectively. The HR for PRFS2 was 0.75 (95 % CI, 0.56–1.01); 48-month PRFS2 rates were 82.5 % for pembrolizumab and 76.7 % for placebo. In the crossover population, median follow-up was 36.9 months; median RFS was not reached (NR; 95 % CI, 16.8-NR; 48-month RFS, 50.6 %) in patients with resectable disease (n = 41) and median progression-free survival was 22.0 months (4.5-NR) in patients with unresectable disease (n = 30). Among patients rechallenged, median follow-up was 21.9 months; none with resectable disease had recurrence (n = 6) and 1 with unresectable disease had best response of stable disease (n = 3). No new safety signals were observed.</div></div><div><h3>Conclusions</h3><div>With &gt; 4 years follow-up, pembrolizumab continued to prolong RFS and DMFS and had antitumor activity in patients who crossed over to pembrolizumab.</div><div>Trial registration: NCT03553836</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"220 ","pages":"Article 115381"},"PeriodicalIF":7.6,"publicationDate":"2025-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143791137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Primary mediastinal B-cell lymphoma (PMBCL): The LYSA pragmatic guidelines","authors":"Loïc Renaud ,&nbsp;Marie Donzel ,&nbsp;Justine Decroocq ,&nbsp;Pierre Decazes ,&nbsp;Jean Galtier ,&nbsp;Barbara Burroni ,&nbsp;Elena-Liana Veresezan ,&nbsp;Côme Sesboüé ,&nbsp;Peggy Dartigues ,&nbsp;Catherine Chassagne-Clément ,&nbsp;Laurent Martin ,&nbsp;Claire Mauduit ,&nbsp;Sophie Kaltenbach ,&nbsp;Dominique Penther ,&nbsp;Pascaline Etancelin ,&nbsp;David Sibon ,&nbsp;Sarah Bailly ,&nbsp;Valentine Martin ,&nbsp;Eric Durot ,&nbsp;Youlia Kirova ,&nbsp;Vincent Camus","doi":"10.1016/j.ejca.2025.115369","DOIUrl":"10.1016/j.ejca.2025.115369","url":null,"abstract":"<div><div>Primary mediastinal B-cell lymphoma (PMBCL) is a distinct subtype of large B-cell lymphoma with unique clinical, histopathological, and molecular characteristics. Despite its aggressive nature, PMBCL has a high cure rate when managed appropriately. Advances in the understanding of PMBCL biological characteristics, coupled with improvements in diagnostic tools and therapeutic approaches, have significantly improved patient outcomes in recent years. In this article, we present a set of pragmatic guidelines developed by the Lymphoma Study Association (LYSA) for the management of PMBCL. These guidelines address key aspects of diagnosis, staging, response evaluation, and treatment, integrating the latest evidence from clinical trials, expert consensus, and real-world practice. The aim of the guidelines is to provide clinicians with a clear, practical framework to optimize care for patients with PMBCL, ensuring that the best available evidence is translated into clinical practice.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"220 ","pages":"Article 115369"},"PeriodicalIF":7.6,"publicationDate":"2025-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143724821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety of accelerated infusion of nivolumab and pembrolizumab","authors":"Loes van Rijssen ,&nbsp;Iris E.C. Nagtegaal ,&nbsp;Floortje K. Ploos van Amstel ,&nbsp;Chantal M.L. Driessen ,&nbsp;Nielka P. van Erp ,&nbsp;Anja Timmer-Bonte ,&nbsp;Sarah R. Verhoeff","doi":"10.1016/j.ejca.2025.115373","DOIUrl":"10.1016/j.ejca.2025.115373","url":null,"abstract":"<div><div>Nivolumab and pembrolizumab are checkpoint inhibitors targeting programmed cell death-1, used for several types of cancer. The increased use of these drugs and the growing number of cancer patients place a significant burden on the hospital ward capacity. Safely reducing the infusion time of immune checkpoint inhibitors could improve capacity. The aim of this implementation project was to explore the safety of accelerated infusion time for nivolumab and pembrolizumab. Patients who received monotherapy nivolumab or pembrolizumab were included in the implementation project. The administration time according to label of nivolumab and pembrolizumab was reduced over 2–3 treatment cycles from 60 and 30–10 min. Vital signs were measured every 15 min from start until 30 min after completion of each administration. If a hypersensitivity reaction (HSR) occurred, infusion was interrupted, and its severity was graded. Between January 2023 and December 2024, 101 patients were enrolled (316 infusions). This included 72 patients with nivolumab and 29 with pembrolizumab treatment. Only grade 1 and 2 HSR were observed. In total 11 HSRs were observed during the administration of nivolumab. Nine HSRs occurred during the 30-minute and two during the 10-minute infusion. No HSR was recorded with pembrolizumab. The accelerated infusion of nivolumab and pembrolizumab in 10 min is safe and results in considerable time efficiency. This strategy is potentially feasible for more immune checkpoint inhibitors and should therefore be considered to facilitate the treatment of the increasing number of cancer patients.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"220 ","pages":"Article 115373"},"PeriodicalIF":7.6,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143705916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}